The relationship between plasma levels of lipoprotein(a) [Lp(a)], PCSK9 and their complex in hypercholesterolemic patients depends on the apolipoprotein(a) phenotype

被引：0
|
作者：
Klesareva, E. A. [1 ]
Afanasieva, O. I. [1 ]
Razova, O. A. [1 ]
Utkina, E. A. [1 ]
Afanasieva, M. I. [1 ]
Ezhov, M. V. [2 ]
Pokrovsky, S. N. [1 ]
机构：
[1] Natl Med Res Ctr Cardiol, Inst Expt Cardiol, Moscow, Russia
[2] Natl Med Res Ctr Cardiol, Inst Clin Cardiol, Moscow, Russia
来源：
EUROPEAN HEART JOURNAL | 2018年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6272
引用
收藏
页码：1305 / 1305
页数：1
相关论文
共 50 条
  • [31] Analysis of the Association between PCSK9 Levels and Plasma Lipid Levels in Cameroonians with Type 2 Diabetes
    Camille, B. M.
    Mbacham, Wilfred F.
    Sobngwi, Eugene
    Mbanya, Jean Claude
    DIABETES, 2018, 67
  • [32] PLASMA PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IS ASSOCIATED WITH LP(A) IN TYPE 2 DIABETIC PATIENTS
    Nekaies, Y.
    Baudin, B.
    Sakly, M.
    Attia, N.
    ATHEROSCLEROSIS, 2015, 241 (01) : E102 - E102
  • [33] Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
    Levstek, Tina
    Karun, Tina
    Likozar, Andreja Rehberger
    Sebestjen, Miran
    Podkrajsek, Katarina Trebusak
    GENES, 2023, 14 (03)
  • [34] PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia
    Alonso, Rodrigo
    Mata, Pedro
    Muniz, Ovidio
    Fuentes-Jimenez, Francisco
    Diaz, Jose Luis
    Zambon, Daniel
    Tomas, Marta
    Martin, Cesar
    Moyon, Thomas
    Croyal, Mikael
    Thedrez, Aurelie
    Lambert, Gilles
    ATHEROSCLEROSIS, 2016, 254 : 249 - 253
  • [35] PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels
    Marais, A. David
    Kim, Jae B.
    Wasserman, Scott M.
    Lambert, Gilles
    PHARMACOLOGY & THERAPEUTICS, 2015, 145 : 58 - 66
  • [36] Correction to: Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese
    Daisuke Nose
    Yuhei Shiga
    Yoko Ueda
    Yoshiaki Idemoto
    Kohei Tashiro
    Yasusnori Suematsu
    Takashi Kuwano
    Ken Kitajima
    Keijiro Saku
    Shin-ichiro Miura
    Heart and Vessels, 2019, 34 : 29 - 32
  • [37] PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration
    Ying, Qidi
    Chan, Dick C.
    Pang, Jing
    Marcovina, Santica M.
    Barrett, Peter Hugh R.
    Watts, Gerald F.
    JOURNAL OF INTERNAL MEDICINE, 2022, 291 (06) : 870 - 876
  • [38] Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9
    Le, Quoc-Tuan
    Blanchet, Matthieu
    Seidah, Nabil G.
    Labonte, Patrick
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (38) : 23385 - 23400
  • [39] Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjogren's Syndrome
    Bianconi, Vanessa
    Cafaro, Giacomo
    Mannarino, Massimo Raffaele
    Perricone, Carlo
    Cosentini, Elena
    Bistoni, Onelia
    Paltriccia, Rita
    Lombardini, Rita
    Gerli, Roberto
    Pirro, Matteo
    Bartoloni, Elena
    BIOMOLECULES, 2023, 13 (09)
  • [40] Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidaemias
    Terentes-Printzios, D.
    Koutagiar, I.
    Vlachopoulos, C.
    Skoumas, I.
    Rigatou, A.
    Miliou, A.
    Skliros, N. P.
    Pantou, S.
    Filis, K.
    Tousoulis, D.
    EUROPEAN HEART JOURNAL, 2018, 39 : 81 - 81
12345